Hyperpigmentation is the term that describes darker skin patches. These patches occur due to excessive production of melanin in the human body, which can also be caused through everything starting from the scars, acne, and also sun damage to the hormone fluctuations. Hyperpigmentation is a common disorder, hence if any individual is suffering from this kind of disease, there is no need to worry and he is not the only individual with the said disease. There are multiple treatment options available for hyperpigmentation.
Hyperpigmentation disorders treatment market is estimated to be over US$ 3.5 Bn in 2017. It is anticipated to grow at a CAGR of 7.0% from 2019 to 2030.
Increasing awareness among patients, technological advancements in the sector of aesthetic treatment of pigmentation related conditions, and growing geriatric population have been pivotal in dictating the growth of the hyperpigmentation disorders treatment market. Moreover, rising adoption of minimally invasive procedure, increasing medical tourism for aesthetics is anticipated to be the major drive the growth of the global hyperpigmentation disorders treatment market between 2019 and 2030.
Major Key Players of the Hyperpigmentation Disorders Treatment Market are:
Bayer AG, RXi Pharmaceuticals, ALLERGAN, Galderma laboratories, SkinCeuticals International, PIERRE FABRE GROUP, EpiPharm AG, Obagi Cosmeceuticals LLC., and VIVIERPHARMA among others
No comments:
Post a Comment